COMPANY PROFILE

Oculeve

Explore full profile

Biotech company focused on developing novel treatments for dry eye

South San Francisco, United StatesFounded 2011Biotech & Life Sciences

Valuation $100–250M Last recorded · 2015

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Oculeve

Oculeve, a subsidiary of Allergan, specializes in developing innovative treatments for dry eye disease through advanced neurostimulation technology. The company primarily serves patients suffering from chronic dry eye conditions, a prevalent issue in the ophthalmology market. Oculeve operates within the healthcare sector, focusing on medical devices and therapeutic solutions. Its business model revolves around the research, development, and commercialization of its proprietary neurostimulation devices, which are designed to stimulate the lacrimal gland and increase tear production. Revenue is generated through the sale of these medical devices to healthcare providers and directly to patients. The company leverages its strong R&D capabilities and strategic partnerships to maintain a competitive edge in the market.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2011
Headquarters: South San Francisco, United States
Employees: 2
Open positions: None listed
Dealroom signal: 55.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Jul 2015	$125M	$125M	Allergan	—
LATE VC✓Equity / VC	Mar 2014	$17M	$66M	NEA · Kleiner Perkins	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Oculeve website traffic

Latest recorded traffic for Oculeve is 180 monthly website visits. Oculeve's team grew 0% over the past year.

Latest monthly visits180 1-year team growth0%

Monthly website visitsApr 2016–Oct 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HAHaiiDeveloping innovative digital therapeutics in the prevention and management of mental health and disease such as dementia, depression, and anxiety disorders	Seoul, South Korea	Operational	—	$9.6M	$25M
AXAxonicsCompany developing novel implantable neuromodulation	Irvine, United States	Acquired
ATAthenexAthenex is focused on the development and commercialization of therapies for cancer and immunomodulatory diseases	Buffalo, United States	Closed
GEGenoptixProvides specialized oncology diagnostics services	Carlsbad, United States	Acquired
BIBitomeReal-time health insights using non-invasive diagnostic products	Boston, United States	Operational
RORapid OxygenPortable emergency oxygen system that can be placed in any location	Westport, United States	Operational
PRProteoMediXIdentification of novel biomarkers for the early detection of cancer	Schlieren, Switzerland	Acquired
ATAvalo TherapeuticsDiscovers, develops and commercializes neuroscience drugs	Rockville, United States	Operational